Rukan GENC, Nilgun YAKUBOGULLARİ, Ayse NALBANTSOY, Fethiye COVEN, Erdal BEDİR

Adjuvant potency of Astragaloside VII embedded cholesterol nanoparticles for H3N2 influenza vaccine

Adjuvants are substances that increase the immune response to a given antigen. In the development of novel vaccine adjuvants/systems, saponins are one of the most attractive molecules due to their altered immunomodulatory activities. In this study, we tried to develop PEG (polyethylene glycol)/cholesterol-based lipid nanoparticles (LNPs) to deliver the Astragaloside VII (AST-VII) and potentiate adjuvant properties of AST-VII for the influenza vaccine. In the formation of PEG/cholesterol/AST-VII-based LNPs (PEG300: Chol-AST-VII LNPs), 3 different primary solvents (acetone, ethanol, and chloroform) were evaluated, employing their effects on hydrodynamic particle size, distribution, surface chemistry, and colloidal stability. Prepared nanoparticles were simply admixtured with inactivated influenza antigen (H3N2) and applied to PMA (phorbol 12-myristate 13-acetate)-ionomycin treated human whole blood to evaluate their cytokine release profile. PEG300: Chol-AST-VII LNPs (80.2 +/- 7.7 nm) were obtained using chloroform as a desolvation agent. Co-treatment of PMA-ionomycin with AST-VII and PEG300: Chol-AST-VII LNPs significantly increased the levels of IL-2 and IFN-gamma, compared to PMA-ionomycin alone. In the presence of H3N2, AST-VII was able to augment IL-17A, while PEG300: Chol-AST-VII LNPs stimulated the production of IFN-gamma. Hemolysis was only observed in PEG300: Chol-AST-VII LNPs (250 mu g/mL) treatment. AST-VII and AST-VII-integrated LNPs could be used as efficacious adjuvants for an inactivated H3N2 vaccine in vitro, and cytokine response through Th1/Th17 route was reported.

Keywords:

Immunomodulatory activity nanocarriers, cholesterol, triterpenoid saponins, Astragaloside VII, influenza,

PDF

___

Alayoubi A, 2013, AAPS J, V15, P1168, DOI 10.1208/s12248-013-9525-z
Allan WH, 1978, THEIR PRODUCTION USE, V10
BAHNEMANN HG, 1975, ARCH VIROL, V47, P47, DOI 10.1007/BF01315592
Barnier-Quer Christophe, 2013, Pharmaceutics, V5, P392, DOI 10.3390/pharmaceutics5030392
Bedir E, 1999, J NAT PROD, V62, P563, DOI 10.1021/np980399t
Campardelli R, 2012, J SUPERCRIT FLUID, V70, P100, DOI 10.1016/j.supflu.2012.06.005
Cano-Sarabia M, 2008, LANGMUIR, V24, P2433, DOI 10.1021/la7032109
Chen WQ, 2013, SCI REP-UK, V3, DOI 10.1038/srep02162
Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011
Du N, 2014, P NATL ACAD SCI USA, V111, P16484, DOI 10.1073/pnas.1417215111
Duewell P, 2011, J IMMUNOL, V187, P55, DOI 10.4049/jimmunol.1004114
Ferrer-Tasies L, 2013, LANGMUIR, V29, P6519, DOI 10.1021/la4003803
Genc R, 2009, LANGMUIR, V25, P12604, DOI 10.1021/la901789h
Guy B, 2007, NAT REV MICROBIOL, V5, P505, DOI 10.1038/nrmicro1681
Han SN, 2000, J INFECT DIS, V182, pS74, DOI 10.1086/315915
Harding AT, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020019
Higaki M, 2005, ANN RHEUM DIS, V64, P1132, DOI 10.1136/ard.2004.030759
Ilyinskii PO, 2014, VACCINE, V32, P2882, DOI 10.1016/j.vaccine.2014.02.027
Jumaa M., 1999, PHARM ACTA HELV, V73, P293, DOI DOI 10.1016/S0031-6865(99)00003-5
Kedmi R, 2010, BIOMATERIALS, V31, P6867, DOI 10.1016/j.biomaterials.2010.05.027
Kommareddy S, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P249, DOI 10.1016/B978-0-12-804019-5.00013-X
Liao W, 2013, IMMUNITY, V38, P13, DOI 10.1016/j.immuni.2013.01.004
Ma XQ, 2002, J AGR FOOD CHEM, V50, P4861, DOI 10.1021/jf0202279
Malyala P, 2010, METHODS MOL BIOL, V626, P91, DOI 10.1007/978-1-60761-585-9_7
Marcus PI, 2005, J VIROL, V79, P2880, DOI 10.1128/JVI.79.5.2880-2890.2005
McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05
Morelli AB, 2012, J MED MICROBIOL, V61, P935, DOI 10.1099/jmm.0.040857-0
Moses T, 2014, CRIT REV BIOCHEM MOL, V49, P439, DOI 10.3109/10409238.2014.953628
Nalbantsoy A, 2012, J ETHNOPHARMACOL, V139, P574, DOI 10.1016/j.jep.2011.11.053
Nalbantsoy A, 2011, J ETHNOPHARMACOL, V134, P897, DOI 10.1016/j.jep.2011.01.054
Rosenkrands I, 2011, VACCINE, V29, P6283, DOI 10.1016/j.vaccine.2011.06.040
Salim NV, 2013, SOFT MATTER, V9, P6176, DOI 10.1039/c3sm50646k
Sardan M, 2013, FARADAY DISCUSS, V166, P269, DOI 10.1039/c3fd00058c
Shi ST, 2019, VACCINE, V37, P3167, DOI 10.1016/j.vaccine.2019.04.055
Shirai S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03018
Shirota H, 2014, EXPERT REV VACCINES, V13, P299, DOI 10.1586/14760584.2014.863715
Sjolander S, 2001, VACCINE, V19, P4072, DOI 10.1016/S0264-410X(01)00110-4
Sun HX, 2009, VACCINE, V27, P4388, DOI 10.1016/j.vaccine.2009.05.032
Wang ZB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010128
Wu TYH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009980
Xu S, 2010, CELL MOL IMMUNOL, V7, P164, DOI 10.1038/cmi.2010.21
Yakubogullari N, 2019, VACCINE, V37, P3638, DOI 10.1016/j.vaccine.2019.05.038
Yesilada E, 2005, J ETHNOPHARMACOL, V96, P71, DOI 10.1016/j.jep.2004.08.036